Aardvark Therapeutics, Inc. has encountered a significant regulatory challenge as the FDA placed a clinical hold on its ARD-101 drug trial due to unexpected cardiac safety signals. This halt means the company's stock is currently valued mostly based on its $91 million cash reserves, with little market value attributed to the drug's prospects. While unblinding trial data could clarify safety issues quickly, it risks compromising trial integrity and would likely require an additional Phase 3 study. Investors are advised to maintain a neutral or hold position until clearer guidance from the FDA emerges, as regulatory decisions will be the key near-term factor for the stock's future.
At Google Next 2026, Google Cloud Security used Instruqt's hands-on platform to train over 150 practitioners on Agentic AI capabilities. Participants built their own AI agents in dedicated Google Cloud Vertex AI environments, gaining practical experi...
Last week, large-cap stocks in sectors like technology, electric vehicles, data centers, and healthcare experienced declines due to weak earnings guidance, regulatory worries, rising bond yields, and increased competition. Notable losers included Int...
The Schall Law Firm is investigating Alphatec Holdings for potential securities law violations after the company missed its Q1 2026 revenue estimates and lowered its full-year revenue outlook. Alphatec admitted to failing to fulfill committed unit de...
Disney's "The Mandalorian and Grogu" earned an estimated $82 million in domestic ticket sales in its first three days, marking the lowest opening for a Disney Star Wars film. Despite this, the film exceeded initial box office predictions and is expec...
Bitcoin's price is heavily influenced by macroeconomic factors, especially expectations around U.S. Federal Reserve rate cuts. Recent comments from Fed Chair Kevin Warsh suggesting openness to rate cuts have boosted optimism in the crypto market. How...
